CDK4 and non-small cell lung carcinoma: In certain patients with immunotherapy-tolerant advanced non-small-cell lung cancer (NSCLC), the combination of CDK4/6 inhibitors and anti-PD-1 agents has shown unexpected clinical benefits [36].